News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

URL Pharma Acquires PharmPro Manufacturing Facility and Equipment


8/3/2009 6:25:32 AM

Bookmark and Share

PHILADELPHIA, Aug. 3 /PRNewswire/ -- URL Pharma, a leading specialty pharmaceutical company, today announced it has acquired the assets of PharmPro, a division of Fluid Air, Inc. The facility, located in Aurora, Illinois, is FDA inspected and DEA (Drug Enforcement Agency) licensed. The acquisition expands the capacity and capabilities of URL Pharma's product development and manufacturing operations.

The 19,000 sq. ft. state-of-the-art facility includes fluid bed technology, enabling water and solvent coating processes critical to the development and manufacture of a wide array of modified release products. The acquisition also includes DuraGran®, a proprietary platform technology that enables the efficient production of uniform, small granules in the development and manufacture of modified release dosage forms.

"This acquisition brings fluid bed technology in-house, enabling us to develop and manufacture a broad range of products for our pharmaceutical technology and brand pipelines," commented Richard H. Roberts, M.D., Ph.D., URL Pharma's President and Chief Executive Officer. "As part of this transaction, 17 former Fluid-Air employees, many with critical engineering expertise, will join URL Pharma and help integrate the new technology into our product development and manufacturing operations."

About URL Pharma

URL Pharma, Inc., headquartered in Philadelphia, Pennsylvania, is a leading specialty pharmaceutical company with fully integrated technology development, product development, manufacturing, and commercialization capabilities. After a long history of generic pharmaceutical research, development, and manufacturing, the Company has successfully transitioned to a profitable, technology-driven, specialty pharmaceutical business. The Company seeks to develop and commercialize scientifically and medically innovative products that address unmet medical needs for improvements in safety and efficacy. The Company's profits are derived predominantly from its exclusive products and technologies. For more information, visit www.urlpharma.com.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES